Adrita Chanda¹, Adrija Aich¹, Arka Sanyal², Anantika Chandra³ and Saumyadeep Goswami³*

¹School of Biosciences and Technology (SBST), Vellore Institute of Technology, Vellore, India

*Corresponding Author: Saumyadeep Goswami, School of Bioscience, Indian Institute of Technology, Kharagpur, Kharagpur, West Bengal, India.

Received: July 04, 2022; Published: July 29, 2022

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak in China's Hubei area in late 2019 has now created a global pandemic that has spread to over 150 countries. In most people, COVID-19 is a respiratory infection that produces fever, cough, and shortness of breath. Patients with severe Covid- 19 may develop ARDS. MSCs can come from a number of places, such as bone marrow, umbilical cord, and adipose tissue. Because of their easy accessibility and low immunogenicity, MSCs were often used in animal and clinical research. In recent studies, MSCs have been shown to decrease inflammation, enhance lung permeability, improve microbial and alveolar fluid clearance, and accelerate lung epithelial and endothelial repair. Furthermore, MSC-based therapy has shown promising outcomes in preclinical studies and phase 1 clinical trials in sepsis and ARDS. In this paper, we posit the therapeutic strategies using MSC and dissect how and why MSC therapy is a potential treatment option for COVID-19-induced ARDS. We cite numerous promising clinical trials, elucidate the potential advantages of MSC therapy for Covid-19 ARDS patients, examine the detriments of this therapeutic strategy and suggest possibilities of subsequent research.

Keywords: Mesenchymal Stem Cell Therapy; Covid-19; Acute Respiratory Distress Syndrome; ARDS

References

1. B Durmaz., et al. “Mutations observed in the SARS-CoV-2 spike glycoprotein and their effects in the interaction of virus with ACE-2 receptor”. Medeniyet Medical Journal3 (2020): 253-260.
2. R Lu., et al. “Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding”. Lancet 10224 (2020): 565-574.
3. M V 2 Domenico Cucinotta 1. “WHO declares COVID 19 a pandemic”.
4. “Symptoms of COVID-19 | CDC” (2021).
5. DL Sykes., et al. “Post-COVID-19 Symptom Burden: What is Long-COVID and How Should We Manage It?”. Lung2 (2021): 113-119.
6. N Gupta., et al. “Intrapulmonary Delivery of Bone Marrow-Derived Mesenchymal Stem Cells Improves Survival and Attenuates Endotoxin- Induced Acute Lung Injury in Mice”. Journal of Immunology3 (2007): 1855-1863.
7. J Devaney., et al. “Human mesenchymal stromal cells decrease the severity of acute lung injury induced by Coli in the rat”. Thorax 70.7 (2015): 625-635.
8. J Li., et al. “Feasibility of Mesenchymal Stem Cell Therapy for COVID-19: A Mini Review”. Current Gene Therapy 4 (2020): 285-288.
9. Z Li., et al. “Stem cell therapy for COVID-19, ARDS and pulmonary fibrosis”. Cell Proliferation12 (2020): 1-15.
10. M Hoffmann., et al. “SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor”. Cell2 (2020): 271-280.e8.
11. K L., et al. “The micromechanics of lung alveoli: structure and function of surfactant and tissue components”. 150.6 (2018): 661-676.
12. M Mittal., et al. “Reactive Oxygen Species in Inflammation and Tissue Injury”. Antioxidants and Redox Signaling 7 (2014): 1126.
13. G H Meftahi., et al. “A vicious circle between oxidative stress and cytokine storm in acute respiratory distress syndrome pathogenesis at covid-19 infection”. Ukrainian Biochemical Journal 1 (2021): 18-29.
14. ME MA., et al. “Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes”. Microbes Infection4-5 (2020): 226-229.
15. Z Varga., et al. “Endothelial cell infection and endotheliitis in COVID-19”. Lancet10234 (2020): 1417-1418.
16. W AJ., et al. “Acute respiratory distress syndrome: epidemiology and management approaches”. Clinical Epidemiology 1 (2012): 159-169.
17. B EL., et al. “The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance”. European Respiratory Journal 1 (2014): 276-285.
18. W WA., et al. “Inflammation-associated remodelling and fibrosis in the lung - a process and an end point”. International Journal of Experimental Pathology 2 (2070): 103-110.
19. E Maxwell. “Living with COVID-19. A dynamic review of the evidence around ongoing covid-19 symptoms (often called long covid)”. National Institutes of Health 3 (2020): 197-200.
20. L X and M X. “Acute respiratory failure in COVID-19: is it ‘typical’ ARDS?”. Critical Care1 (2020).
21. I Bertoncello and J L Mcqualter. “Invited review series: stem cells and the lung series editors: yuben moodley and philip J Thompson Lung stem cells: Do they exist?”. (2013).
22. L KT., et al. “Lung stem and progenitor cells in tissue homeostasis and disease”. Current Topics in Developmental Biology 107 (2014): 207-233.
23. MB Murphy., et al. “Mesenchymal stem cells: Environmentally responsive therapeutics for regenerative medicine”. Experimental and Molecular Medicine11 (2013): 1-16.
24. K Le Blanc and D Mougiakakos. “Multipotent mesenchymal stromal cells and the innate immune system”. Nature Reviews Immunology5 (2012): 383-396.
25. DJ Weiss. “Concise review: Current status of stem cells and regenerative medicine in lung biology and diseases”. Stem Cells1 (2014): 16-25.
26. D E., et al. “Mesenchymal stem cell (MSc) secretome: A possible therapeutic strategy for intensive-care COVID-19 patients”. Medical Hypotheses 142 (2020).
27. T Chen., et al. “Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study”. BMJ 368 (2020).
28. M V., et al. “Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2”. Cell 4 (2020): 905-913.e7.
29. , et al. “Mesenchymal stem cells reduce hypoxia-induced apoptosis in alveolar epithelial cells by modulating HIF and ROS hypoxic signaling”. American Journal of Physiology - Lung Cellular and Molecular Physiology 314.3 (2018): L360-L371.
30. B Li., et al. “Bone marrow mesenchymal stem cells protect alveolar macrophages from lipopolysaccharide-induced apoptosis partially by inhibiting the Wnt/β-catenin pathway”. Cell Biology International 2 (2015): 192-200.
31. LF and KH. “Antiviral Effect of IDO in Mouse Fibroblast Cells During Influenza Virus Infection”. Viral Immunology7 (2017): 542-544.
32. , et al. “Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes”. American Journal of Physiology - Lung Cellular and Molecular Physiology 302.10 (2012).
33. , et al. “Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia”. Thorax 67.6 (2012): 533-539.
34. , et al. “Mesenchymal stem cells reduce hypoxia-induced apoptosis in alveolar epithelial cells by modulating HIF and ROS hypoxic signaling”. American Journal of Physiology - Lung Cellular and Molecular Physiology 314.3 (2018): L360-L371.
35. MCW Chan., et al. “Human mesenchymal stromal cells reduce influenza A H5N1-associated acute lung injury in vitro and in vivo”. Proceedings of the National Academy of Sciences of the United States of America 13 (2016): 3621-3626.
36. M Kavianpour., et al. “The role of mesenchymal stromal cells in immune modulation of COVID-19: Focus on cytokine storm”. Stem Cell Research and Therapy 1 (2020): 1-19.
37. D Baud., et al. “Real estimates of mortality following COVID-19 infection”. Lancet Infectious Disease7 (2020): 773.
38. W Zhang., et al. “The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China”. Clinical Immunology 214 (2020): 108393.
39. D Sharma and F Zhao. “Updates on clinical trials evaluating the regenerative potential of allogenic mesenchymal stem cells in COVID-19”. npj Regenerative Medicine 1 (2021): 1-11.
40. Y Feng., et al. “Safety and feasibility of umbilical cord mesenchymal stem cells in patients with COVID-19 pneumonia: A pilot study”. Cell Proliferation 12 (2020): e12947.
41. B SC., et al. “Telemedicine visits in an established multidisciplinary central nervous system clinic for radiation oncology and neurosurgery (RADIANS) in a community hospital setting”. Lek. Listy 122.9 (2021): 680-683.
42. K Gkatzis., et al. “Use of three-dimensional organoids and lung-on-a-chip methods to study lung development, regeneration and disease”. European Respiratory Journal5 (2018): 1800876.
43. KG Chen., et al. “Studying SARS-CoV-2 infectivity and therapeutic responses with complex organoids”. Nature Cell Biology 238 23.8 (2021): 822-833.
44. SS Hasan., et al. “Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis”. Expert Review of Respiratory Medicine 11 (2020): 1149-1163.
45. E J Panther and B Lucke-Wold. “Subarachnoid hemorrhage: management considerations for COVID-19”. Exploration of Neuroprotective Therapy2 (2022): 65-73.
46. U Jain. “Effect of COVID-19 on the Organs”. Cureus8 (2020).
47. H Zhu., et al. “Therapeutic Effects of Human Umbilical Cord-Derived Mesenchymal Stem Cells in Acute Lung Injury Mice”. Scientific Report 7 (2017).
48. X P Xu., et al. “Genetic Modification of Mesenchymal Stem Cells Overexpressing Angiotensin II Type 2 Receptor Increases Cell Migration to Injured Lung in LPS-Induced Acute Lung Injury Mice”. Stem Cells Translational Medicine10 (2018): 721-730.
49. J Chen., et al. “Keratinocyte Growth Factor Gene Delivery via Mesenchymal Stem Cells Protects against Lipopolysaccharide-Induced Acute Lung Injury in Mice”. PLoS One12 (2013): e83303.
50. X Chen., et al. “Mesenchymal stem cells overexpressing heme oxygenase-1 ameliorate lipopolysaccharide-induced acute lung injury in rats”. Journal of Cell Physiology5 (2019): 7301-7319.
51. SM Chacko., et al. “Hypoxic preconditioning induces the expression of prosurvival and proangiogenic markers in mesenchymal stem cells”. American Journal of Physiology - Cell Physiology6 (2010).
52. M L Bustos., et al. “Activation of Human Mesenchymal Stem Cells Impacts Their Therapeutic Abilities in Lung Injury by Increasing Interleukin (IL)-10 and IL-1RN Levels”. Stem Cells Translational Medicine11 (2013): 884-895.
53. D Li., et al. “Low levels of TGF-β1 enhance human umbilical cord-derived mesenchymal stem cell fibronectin production and extend survival time in a rat model of lipopolysaccharide-induced acute lung injury”. Molecular Medicine Reports 2 (2016): 1681-1692.

Citation

Citation: Saumyadeep Goswami, et al. “Current Landscape of Mesenchymal Stem Cell Therapy in COVID Induced Acute Respiratory Distress Syndrome". Acta Scientific Microbiology 5.8 (2022): 149-162.

Copyright

Copyright: © 2022 Saumyadeep Goswami., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.